From Contract to Patient: Reducing Speed-to-Launch Barriers in Direct-to-Patient Programs

As pharmaceutical companies expand direct-to-patient (DTP) strategies, many continue to face lengthy implementation timelines driven by fragmented technology environments, custom integrations, and complex program requirements. These delays can slow patient access, extend the time between program approval and first prescription fulfillment, and limit a brand's ability to respond quickly to market opportunities. | As pharmaceutical companies expand direct-to-patient (DTP) strategies, many continue to face lengthy implementation timelines driven by fragmented technology environments, custom integrations, and complex program requirements. These delays can slow patient access, extend the time between program approval and first prescription fulfillment, and limit a brand's ability to respond quickly to market opportunities.

Raccontata dafiercepharma.com